Based on its recent analysis of the high throughput multiplexing market, Frost & Sullivan recognizes IntelliCyt with the 2016 North American Frost & Sullivan Award for Product Leadership. IntelliCyt’s unique platform, the iQue® Screener, is an integrated system that is not only scalable, but offers an end-to-end solution to address researchers’ challenges. The platform provides fast, rich, multiplexed information about each cell while ensuring quality of the data obtained.
IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery and immuno-oncology research today announced a collaboration with AstraZeneca to further the development of high throughput biology applications to provide insights into the complex biology of disease.
Delphinus Medical Technologies Inc. is about to graduate. And, after 17 years of research and development and three rounds of venture capital totaling $58.5 million, it will start selling its first devices for ultrasonic detection of breast cancer.
NxThera, Inc. announced today that the sexual function preservation data from the Company’s pivotal IDE trial, which previously established the safety and effectiveness of the Rezūm system to treat benign prostatic hyperplasia (BPH), was presented at the 2016 American Urological Association (AUA) annual meeting in San Diego today.
Venture capital firms in Michigan do better than their counterparts nationally, but women and minorities still account for a small number of investment professionals who work in the industry and the entrepreneurs it supports.